Compare Crispr Therapeutics AG (CRSP) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Wayfair Inc — how do they compare? Crispr Therapeutics AG trades at $53.88 (market cap $5.23B), while Wayfair Inc trades at $103.55 (market cap $14.14B). The key difference: Wayfair Inc is far larger — about 2.7× Crispr Therapeutics AG's market cap, and Wayfair Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | W | |
|---|---|---|
Market Cap | $5.23B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $119.05 |
52-Week Low | $44.34 | $57.40 |
Enterprise Value | $3.65B | $16.47B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Wayfair (W) trades at $106.59, up 2.44% today, showing strong momentum following better-than-expected Q2 2026 earnings. Technical indicators signal a bullish trend with the stock approaching key resistance levels. Fundamentally, the company delivered 7.5% year-over-year revenue growth in Q2 2026, though it continues to operate at a net loss margin of -2.49%. Recent news highlights strong U.S. segment performance and market share gains despite international challenges.
The outlook remains cautiously optimistic with analysts projecting 51.78% buy ratings and a $122 consensus price target, representing 14.4% upside potential. Key risks include persistent unprofitability, high debt-to-asset ratio of 95.11%, and uneven consumer demand. The stock's premium valuation at 151.17x EV/EBITDA requires continued execution on growth and margin expansion targets to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
